$NVIDIA (NVDA.US)$ Not recommended to play its options, bouncing up and down every day, playing the stock market like a bungee jumping machine, a proper options killer.
Buy the underlying stock to hold or sell at any time, hold patiently.
Buy when it drops, sell when it rises.
Tip: When considering buying a stock at a high price, it may be helpful to make an assumption. If I already hold this stock, do I want to sell at this current price? If I do want to sell, then why chase the price higher? Conversely, when considering selling a stock or taking profits, it may help to make another assumption. If I do not hold this stock, do I still want to buy at the current price? If I want to buy, then why take profits?
After thinking with this method, if I am willing to buy a bit more at the current price, then I will continue to hold it!

$MicroStrategy (MSTR.US)$ When you see those institutions easily raising the highest prices, you should know it's over.

Too many people are bullish, so the key is to kill more in the downturn. The key is the Macd and K DJ crossing downwards for the second time...
$NVIDIA (NVDA.US)$

🔴According to the clinical trial results announcement disclosed by the company on November 20, combined with the contents of the telephone conference held on the same day, the results of the clinical trial are summarized below.
⭕ My conclusion is bullish. The stock price dropped today, perhaps to cleanse unstable chips for the next round of uptrend. Currently, the long-term moving average is a strong support. After thorough cleansing, there may be consolidation, followed by another uptrend, then a new round of financing to raise funds for commercialization outside Europe and further expansionary clinical trials of NDA new drugs. Of course, the possibility of the company being acquired at a significant premium cannot be ruled out. Turbo overweight position, continue to hold.
🔴Intoday's telephone conference, company management and Professor John Kastelein emphasized the synergistic effect of obicetrapib when used in combination with evolocumab. This means that the combined effect of the drugs is superior to the sum of the effects of the two drugs used alone. The management stated that the positive results of the TANDEM trial have strengthened the company's confidence in the ongoing PREVAIL trial. Once PREVAIL is successful in the future, the company valuation is expected to double.
————
🔥Interpretation of TANDEM Trial Results🔥
🔴Primary Endpoint: Percentage Reduction in LDL-C
Day 84:
Monotherapy with Evymlozumab: LDL-C decreased by 23.3% compared to placebo.
Monotherapy with Obicetrapib: LDL-C decreased by 31.5% compared to placebo.
O...